Recent research has introduced an intriguing development in the realm of weight loss medications. Eli Lilly’s experimental drug, eloralintide, has demonstrated significant weight loss results—differing from established drugs like Ozempic in its mechanism.
In a study published in The Lancet earlier this month, researchers revealed the phase II trial outcomes for eloralintide. Participants in the study lost as much as 20% of their initial body weight over the course of 48 weeks, outperforming those who received a placebo. This early success is particularly striking since eloralintide does not fall within the GLP-1 category of medications.
A Different Mechanism
Eloralintide simulates amylin, a hormone that our pancreas releases alongside insulin when we eat. Amylin essentially signals to our body that we’re full, curbing appetite and slowing down digestion.
The leading weight loss drugs currently—like semaglutide, found in Ozempic and Wegovy—are long-lasting mimics of GLP-1. While both amylin and GLP-1 play roles in controlling hunger and blood sugar, there are important differences between them. This has positioned amylin as a promising new candidate for obesity treatments.
There is a previous amylin-based drug, pramlintide, which has been available for around 20 years to treat diabetes. However, the latest amylin analogues, such as eloralintide, are creating buzz in the scientific community. These newer drugs aim to remain active in the body longer than natural amylin, which could enhance their effectiveness in promoting weight loss and managing blood sugar levels. Similar to semaglutide, eloralintide is planned for weekly subcutaneous injections.
Early Promise
The phase II trial by Eli Lilly consisted of 263 participants suffering from obesity (defined as a body mass index over 30) or overweight individuals (BMI over 27) with related health issues, all of whom do not have type 2 diabetes. They were randomly assigned to receive either a placebo or various doses of eloralintide, with some maintaining a constant dosage and others gradually increasing theirs.
The results revealed that all participants taking eloralintide lost significantly more weight on average compared to those on the placebo. Those receiving the highest weekly dose of nine milligrams experienced the most significant average weight reduction of 20%. Similarly, those who increased their dosage from six to nine milligrams also showed marked improvement.
In terms of safety, the drug appeared to be well-tolerated with typical adverse events being gastrointestinal, aligning with known side effects of GLP-1 therapies. Nausea was the most frequently reported issue, affecting around one-third of those on the highest dose.
The researchers stated, “Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide’s potential use for obesity treatment.”
What Does This Mean for the Future of Weight Loss?
GLP-1s have revolutionized obesity treatment in recent years, and while these drugs come with certain risks and high costs, they have led to a notable decrease in obesity rates in the U.S. The number of obesity medications in development has increased, with many being variations of GLP-1 or combinations of GLP-1 and other hunger-related hormones, including amylin. Eloralintide’s results are particularly exciting because it exclusively targets amylin, potentially offering a viable option for individuals who haven’t seen results with GLP-1 therapies.
However, it’s premature to draw any definitive conclusions, particularly in the absence of trials directly comparing these medications. That said, it’s interesting to note that clinical trials for semaglutide indicated average weight loss of around 15%, while Eli Lilly’s existing drug tirzepatide has shown similar results hovering around 20%.
Of course, further research, particularly from more extensive trials, is essential to validate these findings. If eloralintide continues to show promise, it could pioneer a new frontier in obesity treatment.
